Loading...
Market
Story
Roche Acquires Poseida for $9.00 per Share, Total Deal Value Up to $1.5 Billion, Representing 215% Premium
Nov 26, 2024, 08:59 AM
Roche Holdings, Inc. has entered into a definitive agreement to acquire Poseida Therapeutics, Inc. for an initial cash payment of $9.00 per share, totaling approximately $1 billion. The deal includes a contingent value right (CVR) that could add up to $4.00 per share, bringing the total potential value of the acquisition to $1.5 billion. This strategic move aims to enhance Roche's portfolio in cell therapies, particularly in the treatment of hematological malignancies and solid tumors. Poseida, known for its development of off-the-shelf CAR-T therapies, has been recognized for its innovative technologies in the biopharmaceutical sector. The acquisition represents a significant premium of around 215% over Poseida's recent closing stock price of $2.86, highlighting Roche's commitment to expanding its capabilities in the cell therapy market.
View original story
Similar markets
Stock price above $50 • 25%
Stock price between $20 and $50 • 25%
Stock price between $5 and $20 • 25%
Stock price below $5 • 25%
Significant progress • 25%
Moderate progress • 25%
Little progress • 25%
No progress • 25%
Above $25 • 25%
$20-$25 • 25%
$15-$20 • 25%
Below $15 • 25%
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Above $50 • 25%
$30 to $50 • 25%
$10 to $30 • 25%
Below $10 • 25%
Below $20 • 25%
$20 to $40 • 25%
$40 to $60 • 25%
Above $60 • 25%
Below $150 • 25%
$150 - $175 • 25%
$175 - $200 • 25%
Above $200 • 25%
Below $300 • 25%
$300 to $350 • 25%
$350 to $400 • 25%
Above $400 • 25%
Below $5 • 25%
$5 to $7.49 • 25%
$7.50 to $9.99 • 25%
$10 or above • 25%
Below $40 • 25%
$40 to $45 • 25%
$45 to $50 • 25%
Above $50 • 25%
